NCT03753659 2026-03-23
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Case Comprehensive Cancer Center
Amgen
Sun Yat-sen University
University of Chicago
International Extranodal Lymphoma Study Group (IELSG)
Washington University School of Medicine